<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4962">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02002702</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A1201</org_study_id>
    <nct_id>NCT02002702</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study to assess safety,
      tolerability and pharmacokinetics and to explore efficacy of IV infusion of 10 µg/kg/day and
      30 µg/kg/day serelaxin for 48 hours compared to placebo, when added to the standard therapy,
      in approximately 45 Japanese AHF patients. This study is intended to support registration of
      serelaxin for the treatment of AHF in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients with total adverse events, serious adverse events and death</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events will be assessed through day 5 and serious adverse events through day 14.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of serelaxin: steady-state concentration (Css)</measure>
    <time_frame>From baseline to 56 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of serelaxin: rate of clearance (CL)</measure>
    <time_frame>From baseline to 56 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) for changes in systolic blood pressure (SBP) through 48 hours of infusion and through Day 5</measure>
    <time_frame>From baseline to through 48 hours of infusion and through Day 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood pressure measurements will be done for 30 &amp; 60 minutes and then every hour for the first 6 hours of study drug infusion, and then every 3 hours during study drug infusion, including night time hours. Post-infusion, blood pressure are to be measured every 3 hours until 12 hours following end of infusion, then every 6 hours for 48 hours and then every 24 hours until the earlier of Day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardio-renal biomarkers through Day 14</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in cardio-renal biomarkers will be summarized by treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Serelaxin dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive continuous intravenous infusion of serelaxin for 48 hours at dose 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serelaxin dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive continuous intravenous infusion of serelaxin for 48 hours at dose 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Serelaxin dose 1</arm_group_label>
    <arm_group_label>Serelaxin dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any study-specific assessment is
             performed.

          -  Male or female ≥20 years of age, with body weight ≥30 kg and ≤160 kg

          -  Hospitalized for AHF; AHF is defined as including all of the followings measured at
             any time between presentation (including the emergency department) and the end of
             screening:

          -  Dyspnea at rest or with minimal exertion

          -  Pulmonary congestion on chest radiograph

          -  BNP ≥350 pg/mL or NT-proBNP ≥1,400 pg/mL

          -  SBP ≥125 mmHg at the start and at the end of screening

          -  Able to be randomized within 16 hours from presentation to the hospital, including
             the emergency department

          -  Received intravenous (IV) furosemide of at least 40 mg (or equivalent) at any time
             between presentation (this include outpatient clinic, ambulance, or hospital
             including emergency department) and the start of screening for the study for the
             treatment of the current acute heart failure (HF) episode.

          -  Impaired renal function defined as an estimated glomerular filtration rate (eGFR)
             between presentation and randomization of ≥ 25 and≤ 75 mL/min/1.73 m2, calculated
             using the Japanese formula

        Exclusion Criteria:

          -  Dyspnea primarily due to non-cardiac causes

          -  Temperature &gt;38.5°C (oral or equivalent) or sepsis or active infection requiring IV
             anti-microbial treatment

          -  Clinical evidence of acute coronary syndrome currently or within 30 days prior to
             enrollment.

          -  AHF due to significant arrhythmias, which include any of the following: sustained
             ventricular tachycardia, bradycardia with sustained ventricular rate &lt;45 beats per
             minute, or atrial fibrillation/flutter with sustained ventricular response of &gt;130
             beats per minute.

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seto-city</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <zip>730-8518</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki-city</city>
        <state>Hyogo</state>
        <zip>660-0828</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Higashiibaraki-gun</city>
        <state>Ibaraki</state>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>981-3107</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ueda-city</city>
        <state>Nagano</state>
        <zip>386-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Komatsushima-city</city>
        <state>Tokushima</state>
        <zip>773-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>December 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute heart failure (AHF),</keyword>
  <keyword>Japanese,</keyword>
  <keyword>Safety and tolerability, Pharmacokinetics,</keyword>
  <keyword>Renal Impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
